CA Patent

CA3006300C — Bicyclic bet bromodomain inhibitors and uses thereof

Assigned to ConverGene LLC · Expires 2024-02-27 · 2y expired

What this patent protects

The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treat…

USPTO Abstract

The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA3006300C
Jurisdiction
CA
Classification
Expires
2024-02-27
Drug substance claim
No
Drug product claim
No
Assignee
ConverGene LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.